Abstract
Herein we present a multidisciplinary discussion of ribonucleotide reductase (RNR), the essential enzyme uniquely responsible for conversion of ribonucleotides to deoxyribonucleotides. This chapter primarily presents an overview of this multifaceted and complex enzyme, covering RNR’s role in enzymology, biochemistry, medicinal chemistry, and cell biology. It further focuses on RNR from mammals, whose interesting and often conflicting roles in health and disease are coming more into focus. We present pitfalls that we think have not always been dealt with by researchers in each area and further seek to unite some of the field-specific observations surrounding this enzyme. Our work is thus not intended to cover any one topic in extreme detail, but rather give what we consider to be the necessary broad grounding to understand this critical enzyme holistically. Although this is an approach we have advocated in many different areas of scientific research, there is arguably no other single enzyme that embodies the need for such broad study than RNR. Thus, we submit that RNR itself is a paradigm of interdisciplinary research that is of interest from the perspective of the generalist and the specialist alike. We hope that the discussions herein will thus be helpful to not only those wanting to tackle RNR-specific problems, but also those working on similar interdisciplinary projects centering around other enzymes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmad MF, Huff SE, Pink J et al (2015) Identification of non-nucleoside human ribonucleotide reductase modulators. J Med Chem 58:9498–9509. https://doi.org/10.1021/acs.jmedchem.5b00929
Ahmad MF, Alam I, Huff SE et al (2017) Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule. Proc Natl Acad Sci U S A 114:8241–8246. https://doi.org/10.1073/pnas.1620220114
Akdemir F, Christich A, Sogame N et al (2007) p53 directs focused genomic responses in Drosophila. Oncogene 26:5184–5193. https://doi.org/10.1038/sj.onc.1210328
Akita H, Zheng Z, Takeda Y et al (2009) Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28:2903–2909. https://doi.org/10.1038/onc.2009.158
Aly MS, Ashour MB, El Nahas SM, Abo Zeid MAF (2003) Genotoxicity and cytotoxicity of the anticancer drugs gemcitabine and cisplatin, separately and in combination: in vivo studies. J Biol Sci 3:961–972. https://doi.org/10.3923/jbs.2003.961.972
Ando N, Li H, Brignole EJ et al (2016) Allosteric inhibition of human ribonucleotide reductase by dATP entails the stabilization of a hexamer. Biochemistry 55:373–381. https://doi.org/10.1021/acs.biochem.5b01207
Apraiz A, Mitxelena J, Zubiaga A (2017) Studying cell cycle-regulated gene expression by two complementary cell synchronization protocols. JoVE. https://doi.org/10.3791/55745
Arnaoutov A, Dasso M (2014) IRBIT is a novel regulator of ribonucleotide reductase in higher eukaryotes. Science 345:1512–1515. https://doi.org/10.1126/science.1251550
Arnaoutov A, Lee H, Plevock Haase K et al (2020) IRBIT directs differentiation of intestinal stem cell progeny to maintain tissue homeostasis. iScience 23:100954. https://doi.org/10.1016/j.isci.2020.100954
Aydemir N, Çelikler S, Bilaloğlu R (2005) In vitro genotoxic effects of the anticancer drug gemcitabine in human lymphocytes. Mutat Res 582:35–41. https://doi.org/10.1016/j.mrgentox.2004.12.013
Aye Y, Brignole EJ, Long MJC et al (2012) Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers. Chem Biol 19:799–805. https://doi.org/10.1016/j.chembiol.2012.05.015
Aye Y, Li M, Long MJC, Weiss RS (2015) Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene 34:2011–2021. https://doi.org/10.1038/onc.2014.155
Aye Y, Stubbe J (2011) Clofarabine 5′-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit. Proc Natl Acad Sci USA 108:9815–9820. https://doi.org/10.1073/pnas.1013274108
Bao Q, Shi Y (2007) Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 14:56–65. https://doi.org/10.1038/sj.cdd.4402028
Bepler G, Sharma S, Cantor A, et al (2004) RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non–small-cell lung cancer. JCO 22:1878–1885. https://doi.org/10.1200/JCO.2004.12.002
Bo H, Weiyang C, Zhang Y (2017) p53R2 is oncogenic in human cervical cancer. Cell Cycle 16:1323–1324. https://doi.org/10.1080/15384101.2017.1337978
Bonifati S, Daly MB, St. Gelais C et al (2016) SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology 495:92–100. https://doi.org/10.1016/j.virol.2016.05.002
Bonneau B, Ando H, Kawaai K et al (2016) IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact. eLife 5:e19896. https://doi.org/10.7554/eLife.19896
Borel F, Lacroix FB, Margolis RL (2002) Prolonged arrest of mammalian cells at the G1/S boundary results in permanent S phase stasis. J Cell Sci 115:2829–2838. https://doi.org/10.1242/jcs.115.14.2829
Boronat S, Domènech A, Carmona M et al (2017) Lack of a peroxiredoxin suppresses the lethality of cells devoid of electron donors by channelling electrons to oxidized ribonucleotide reductase. PLoS Genet 13:e1006858. https://doi.org/10.1371/journal.pgen.1006858
Brignole EJ, Tsai K-L, Chittuluru J et al (2018) 3.3-Å resolution cryo-EM structure of human ribonucleotide reductase with substrate and allosteric regulators bound. eLife 7:e31502. https://doi.org/10.7554/eLife.31502
Buckland RJ, Watt DL, Chittoor B et al (2014) Increased and imbalanced dNTP pools symmetrically promote both leading and lagging strand replication infidelity. PLoS Genet 10:e1004846. https://doi.org/10.1371/journal.pgen.1004846
Burkhalter MD, Roberts SA, Havener JM, Ramsden DA (2009) Activity of ribonucleotide reductase helps determine how cells repair DNA double strand breaks. DNA Repair 8:1258–1263. https://doi.org/10.1016/j.dnarep.2009.07.009
Cao M-Y, Lee Y, Feng N-P et al (2003) Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res 9:4553–4561
Caras IW, Martin DW (1988) Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells. Mol Cell Biol 8:2698–2704. https://doi.org/10.1128/mcb.8.7.2698-2704.1988
Çelik H, Sciandra M, Flashner B et al (2018) Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. Oncogene 37:2181–2196. https://doi.org/10.1038/s41388-017-0080-4
Chabes A, Stillman B (2007) Constitutively high dNTP concentration inhibits cell cycle progression and the DNA damage checkpoint in yeast Saccharomyces cerevisiae. Proc Natl Acad Sci 104:1183–1188. https://doi.org/10.1073/pnas.0610585104
Chabes A, Domkin V, Thelander L (1999) Yeast Sml1, a protein inhibitor of ribonucleotide reductase. J Biol Chem 274:36679–36683. https://doi.org/10.1074/jbc.274.51.36679
Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol Mech Dis 4:127–150. https://doi.org/10.1146/annurev.pathol.4.110807.092311
Chen C-W, Tsao N, Huang L-Y et al (2016) The impact of dUTPase on ribonucleotide reductase-induced genome instability in cancer cells. Cell Rep 16:1287–1299. https://doi.org/10.1016/j.celrep.2016.06.094
Chen J, Li S, Xiao Y et al (2017) p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma. BMC Cancer 17:846. https://doi.org/10.1186/s12885-017-3858-4
Chen PY-T, Funk MA, Brignole EJ, Drennan CL (2018) Disruption of an oligomeric interface prevents allosteric inhibition of Escherichia coli class Ia ribonucleotide reductase. J Biol Chem 293:10404–10412. https://doi.org/10.1074/jbc.RA118.002569
Chen G, Luo Y, Warncke K et al (2019a) Acetylation regulates ribonucleotide reductase activity and cancer cell growth. Nat Commun 10:3213. https://doi.org/10.1038/s41467-019-11214-9
Chen W, Yang L, Xu L et al (2019b) Bioinformatics analysis revealing prognostic significance of RRM2 gene in breast cancer. Biosci Rep 39:BSR20182062. https://doi.org/10.1042/BSR20182062
Chimploy K, Mathews CK (2001) Mouse ribonucleotide reductase control. J Biol Chem 276:7093–7100. https://doi.org/10.1074/jbc.M006232200
Chimploy K, Tassotto ML, Mathews CK (2000) Ribonucleotide reductase, a possible agent in deoxyribonucleotide pool asymmetries induced by hypoxia. J Biol Chem 275:39267–39271. https://doi.org/10.1074/jbc.M006233200
Cho EC, Yen Y (2016) Novel regulators and molecular mechanisms of p53R2 and its disease relevance. Biochimie 123:81–84. https://doi.org/10.1016/j.biochi.2016.01.008
Cho E-C, Kuo M-L, Liu X et al (2014) Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients. Oncotarget 5:4834–4844. https://doi.org/10.18632/oncotarget.2044
Cooper GM (2000) The eukaryotic cell cycle. In: The cell: a molecular approach, 2nd edn. Sinauer Associates, Sunderland, MA
Cotruvo JA, Stubbe J (2011) Class I ribonucleotide reductases: metallocofactor assembly and repair in vitro and in vivo. Annu Rev Biochem 80:733–767. https://doi.org/10.1146/annurev-biochem-061408-095817
Daddacha W, Koyen AE, Bastien AJ et al (2017) SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination. Cell Rep 20:1921–1935. https://doi.org/10.1016/j.celrep.2017.08.008
Daly MB, Roth ME, Bonnac L et al (2016) Dual anti-HIV mechanism of clofarabine. Retrovirology 13:20. https://doi.org/10.1186/s12977-016-0254-0
Danilova N, Bibikova E, Covey TM et al (2014) The role of DNA damage response in zebrafish and cellular models of diamond Blackfan anemia. Dis Models Mech. https://doi.org/10.1242/dmm.015495
Deforche K, Camacho R, Laethem KV et al (2007) Estimating the relative contribution of dNTP Pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J Comput Biol 14:1105–1114. https://doi.org/10.1089/cmb.2007.0073
Ding Y, Zhong T, Wang M et al (2019) Integrative analysis reveals across-cancer expression patterns and clinical relevance of ribonucleotide reductase in human cancers. Front Oncol 9:956. https://doi.org/10.3389/fonc.2019.00956
Domkin V, Chabes A (2014) Phosphines are ribonucleotide reductase reductants that act via C-terminal cysteines similar to thioredoxins and glutaredoxins. Sci Rep 4:5539. https://doi.org/10.1038/srep05539
Dyavaiah M, Rooney JP, Chittur SV et al (2011) Autophagy-dependent regulation of the DNA damage response protein ribonucleotide reductase 1. Mol Cancer Res 9:462–475. https://doi.org/10.1158/1541-7786.MCR-10-0473
Elledge SJ, Davis RW (1990) Two genes differentially regulated in the cell cycle and by DNA-damaging agents encode alternative regulatory subunits of ribonucleotide reductase. Genes Dev 4:740–751. https://doi.org/10.1101/gad.4.5.740
Fairman JW, Wijerathna SR, Ahmad MF et al (2011) Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol 18:316–322. https://doi.org/10.1038/nsmb.2007
Fan H, Huang A, Villegas C, Wright JA (1997) The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci 94:13181–13186. https://doi.org/10.1073/pnas.94.24.13181
Fan P, Liu L, Yin Y et al (2016) MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Lett 373:130–137. https://doi.org/10.1016/j.canlet.2016.01.038
Fang Z, Gong C, Liu H et al (2015) E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. Biochem Biophys Res Commun 464:407–415. https://doi.org/10.1016/j.bbrc.2015.06.103
Fang Z, Lin A, Chen J et al (2016) CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer. Oncotarget 7:78055–78068. https://doi.org/10.18632/oncotarget.12938
Fasullo M, Tsaponina O, Sun M, Chabes A (2010) Elevated dNTP levels suppress hyper-recombination in Saccharomyces cerevisiae S-phase checkpoint mutants. Nucleic Acids Res 38:1195–1203. https://doi.org/10.1093/nar/gkp1064
Fiorentini P, Huang KN, Tishkoff DX et al (1997) Exonuclease I of Saccharomyces cerevisiae functions in mitotic recombination in vivo and in vitro. Mol Cell Biol 17:2764–2773. https://doi.org/10.1128/MCB.17.5.2764
Fleck O, Vejrup-Hansen R, Watson A et al (2013) Spd1 accumulation causes genome instability independently of ribonucleotide reduction but functions to protect the genome when deoxynucleotide pools are elevated. J Cell Sci. https://doi.org/10.1242/jcs.132837
Foskolou IP, Jorgensen C, Leszczynska KB et al (2017) Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication. Mol Cell 66:206–220.e9. https://doi.org/10.1016/j.molcel.2017.03.005
Franzolin E, Pontarin G, Rampazzo C et al (2013) The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc Natl Acad Sci 110:14272–14277. https://doi.org/10.1073/pnas.1312033110
Fu Y, Long MJC, Rigney M et al (2013) Uncoupling of allosteric and oligomeric regulation in a functional hybrid enzyme constructed from Escherichia coli and human ribonucleotide reductase. Biochemistry 52:7050–7059. https://doi.org/10.1021/bi400781z
Fu Y, Lin H-Y, Wisitpitthaya S et al (2014) A fluorimetric readout reporting the kinetics of nucleotide-induced human ribonucleotide reductase oligomerization. ChemBioChem 15:2598–2604. https://doi.org/10.1002/cbic.201402368
Fu Y, Long MJC, Wisitpitthaya S et al (2018) Nuclear RNR-α antagonizes cell proliferation by directly inhibiting ZRANB3. Nat Chem Biol 14:943–954. https://doi.org/10.1038/s41589-018-0113-5
Gan H, Yu C, Devbhandari S et al (2017) Checkpoint kinase Rad53 couples leading- and lagging-strand DNA synthesis under replication stress. Mol Cell 68:446–455.e3. https://doi.org/10.1016/j.molcel.2017.09.018
Gandhi V, Plunkett W (2006) Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol 18:584–590. https://doi.org/10.1097/01.cco.0000245326.65152.af
Gautam A, Li Z-R, Bepler G (2003) RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene 22:2135–2142. https://doi.org/10.1038/sj.onc.1206232
Ge J, Yu G, Ator MA, Stubbe J (2003) Pre-steady-state and steady-state kinetic analysis of E. coli class I ribonucleotide reductase. Biochemistry 42:10071–10083. https://doi.org/10.1021/bi034374r
Glover TW, Wilson TE, Arlt MF (2017) Fragile sites in cancer: more than meets the eye. Nat Rev Cancer 17:489–501. https://doi.org/10.1038/nrc.2017.52
Gon S, Napolitano R, Rocha W et al (2011) Increase in dNTP pool size during the DNA damage response plays a key role in spontaneous and induced-mutagenesis in Escherichia coli. Proc Natl Acad Sci 108:19311–19316. https://doi.org/10.1073/pnas.1113664108
Goss KL, Koppenhafer SL, Waters T et al (2021) The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene 40:564–577. https://doi.org/10.1038/s41388-020-01552-0
Greene BL, Nocera DG, Stubbe J (2018) Basis of dATP inhibition of RNRs. J Biol Chem 293:10413–10414. https://doi.org/10.1074/jbc.H118.003717
Grossi F, Dal Bello MG, Salvi S et al (2015) Expression of ribonucleotide reductase subunit-2 and thymidylate synthase correlates with poor prognosis in patients with resected stages I–III non-small cell lung cancer. Dis Markers 2015:1–18. https://doi.org/10.1155/2015/302649
Guzmán EC, Caballero JL, Jiménez-Sánchez A (2002) Ribonucleoside diphosphate reductase is a component of the replication hyperstructure in Escherichia coli: ribonucleoside diphosphate reductase in the replication complex. Mol Microbiol 43:487–495. https://doi.org/10.1046/j.1365-2958.2002.02761.x
Håkansson P, Hofer A, Thelander L (2006) Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 281:7834–7841. https://doi.org/10.1074/jbc.M512894200
Hämäläinen RH, Landoni JC, Ahlqvist KJ et al (2019) Defects in mtDNA replication challenge nuclear genome stability through nucleotide depletion and provide a unifying mechanism for mouse progerias. Nat Metab 1:958–965. https://doi.org/10.1038/s42255-019-0120-1
Hogbom M, Galander M, Andersson M et al (2003) Displacement of the tyrosyl radical cofactor in ribonucleotide reductase obtained by single-crystal high-field EPR and 1.4-A x-ray data. Proc Natl Acad Sci 100:3209–3214. https://doi.org/10.1073/pnas.0536684100
Hoyer J, Ekici AB, Endele S et al (2012) Haploinsufficiency of ARID1B, a member of the SWI/SNF-A chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet 90:565–572. https://doi.org/10.1016/j.ajhg.2012.02.007
Hu C-M, Yeh M-T, Tsao N et al (2012) Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. Cancer Cell 22:36–50. https://doi.org/10.1016/j.ccr.2012.04.038
Huberts DHEW, van der Klei IJ (2010) Moonlighting proteins: an intriguing mode of multitasking. Biochim Biophys Acta 1803:520–525. https://doi.org/10.1016/j.bbamcr.2010.01.022
Huff SE, Mohammed FA, Yang M et al (2018) Structure-guided synthesis and mechanistic studies reveal sweetspots on naphthyl salicyl hydrazone scaffold as non-nucleosidic competitive, reversible inhibitors of human ribonucleotide reductase. J Med Chem 61:666–680. https://doi.org/10.1021/acs.jmedchem.7b00530
Jeffery CJ (2020) Enzymes, pseudoenzymes, and moonlighting proteins: diversity of function in protein superfamilies. FEBS J 287:4141–4149. https://doi.org/10.1111/febs.15446
Ji X, Tang C, Zhao Q et al (2014) Structural basis of cellular dNTP regulation by SAMHD1. Proc Natl Acad Sci 111:E4305–E4314. https://doi.org/10.1073/pnas.1412289111
Jiang K, Zhi T, Xu W et al (2017) MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1. Am J Cancer Res 7:784–800
Jonna VR, Crona M, Rofougaran R et al (2015) Diversity in overall activity regulation of ribonucleotide reductase. J Biol Chem 290:17339–17348. https://doi.org/10.1074/jbc.M115.649624
Kang G, Taguchi AT, Stubbe J, Drennan CL (2020) Structure of a trapped radical transfer pathway within a ribonucleotide reductase holocomplex. Science 368:424–427. https://doi.org/10.1126/science.aba6794
Kauppi B, Nielsen BB, Ramaswamy S et al (1996) The three-dimensional structure of mammalian ribonucleotide reductase protein R2 reveals a more-accessible iron-radical site than Escherichia coliR2. J Mol Biol 262:706–720. https://doi.org/10.1006/jmbi.1996.0546
Ke P-Y, Chang Z-F (2004) Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-Cdh1-mediated pathway. Mol Cell Biol 24:514–526. https://doi.org/10.1128/MCB.24.2.514-526.2004
Knappenberger AJ, Ahmad MF, Viswanathan R et al (2016) Nucleoside analogue triphosphates allosterically regulate human ribonucleotide reductase and identify chemical determinants that drive substrate specificity. Biochemistry 55:5884–5896. https://doi.org/10.1021/acs.biochem.6b00594
Knappenberger AJ, Grandhi S, Sheth R et al (2017) Phylogenetic sequence analysis and functional studies reveal compensatory amino acid substitutions in loop 2 of human ribonucleotide reductase. J Biol Chem 292:16463–16476. https://doi.org/10.1074/jbc.M117.798769
Knox JJ, Hotte SJ, Kollmannsberger C et al (2007) Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada clinical trials group (NCIC IND.161). Investig New Drugs 25:471–477. https://doi.org/10.1007/s10637-007-9044-9
Kong Z, Jia S, Chabes AL et al (2018) Simultaneous determination of ribonucleoside and deoxyribonucleoside triphosphates in biological samples by hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry. Nucleic Acids Res 46:e66–e66. https://doi.org/10.1093/nar/gky203
Kunos CA, Andrews SJ, Moore KN et al (2019) Randomized phase II trial of triapine-cisplatin-radiotherapy for locally advanced stage uterine cervix or vaginal cancers. Front Oncol 9:1067. https://doi.org/10.3389/fonc.2019.01067
Lam MH, Liu Q, Elledge SJ, Rosen JM (2004) Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6:45–59. https://doi.org/10.1016/j.ccr.2004.06.015
Lamb NA, Bard J, Buck MJ, Surtees JA (2020) A targeted next generation sequencing approach to develop robust, genotype-specific mutation profiles and uncover novel variants in Saccharomyces cerevisiae. Genetics
Le François BG, Maroun JA, Birnboim HC (2007) Expression of thymidylate synthase in human cells is an early G1 event regulated by CDK4 and p16INK4A but not E2F. Br J Cancer 97:1242–1250. https://doi.org/10.1038/sj.bjc.6604020
Lee YD, Elledge SJ (2006) Control of ribonucleotide reductase localization through an anchoring mechanism involving Wtm1. Genes Dev 20:334–344. https://doi.org/10.1101/gad.1380506
Lee JJ, Maeng CH, Baek SK et al (2010) The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 70:205–210. https://doi.org/10.1016/j.lungcan.2010.02.005
Lee M-H, Wang L, Chang Z-F (2014) The contribution of mitochondrial thymidylate synthesis in preventing the nuclear genome stress. Nucleic Acids Res 42:4972–4984. https://doi.org/10.1093/nar/gku152
Leeds JM, Slabaugh MB, Mathews CK (1985) DNA precursor pools and ribonucleotide reductase activity: distribution between the nucleus and cytoplasm of mammalian cells. Mol Cell Biol 5:3443–3450. https://doi.org/10.1128/MCB.5.12.3443
Liew LP, Lim ZY, Cohen M et al (2016) Hydroxyurea-mediated cytotoxicity without inhibition of ribonucleotide reductase. Cell Rep 17:1657–1670. https://doi.org/10.1016/j.celrep.2016.10.024
Lim AZ, McFarland R, Taylor RW, Gorman GS (1993) RRM2B mitochondrial DNA maintenance defects. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews®. University of Washington, Seattle, WA
Liu X, Lai L, Wang X et al (2011) Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res 71:3202–3213. https://doi.org/10.1158/0008-5472.CAN-11-0054
Long MJC, Zhao Y, Aye Y (2020) Clofarabine commandeers the RNR-α-ZRANB3 nuclear signaling axis. Cell Chem Biol 27:122–133.e5. https://doi.org/10.1016/j.chembiol.2019.11.012
Lopez-Contreras AJ, Specks J, Barlow JH et al (2015) Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. Genes Dev 29:690–695. https://doi.org/10.1101/gad.256958.114
Lou M, Liu Q, Ren G et al (2017) Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. J Biol Chem 292:9136–9149. https://doi.org/10.1074/jbc.M117.783365
Lundin D, Berggren G, Logan D, Sjöberg B-M (2015) The origin and evolution of ribonucleotide reduction. Life 5:604–636. https://doi.org/10.3390/life5010604
Ma CX, Suman V, Goetz MP et al (2017) A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer. Clin Cancer Res 23:6823–6832. https://doi.org/10.1158/1078-0432.CCR-17-1260
Ma C, Luo H, Cao J et al (2020) Independent prognostic implications of RRM2 in lung adenocarcinoma. J Cancer 11:7009–7022. https://doi.org/10.7150/jca.47895
Mah V, Alavi M, Márquez-Garbán DC et al (2015) Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status. PLoS One 10:e0127600. https://doi.org/10.1371/journal.pone.0127600
Malik L, Zwiebel A, Cooper J (2018) A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors. Cancer Chemother Pharmacol 82:533–539. https://doi.org/10.1007/s00280-018-3647-z
Mannava S, Moparthy KC, Wheeler LJ et al (2013) Depletion of Deoxyribonucleotide pools is an endogenous source of DNA damage in cells undergoing oncogene-induced senescence. Am J Pathol 182:142–151. https://doi.org/10.1016/j.ajpath.2012.09.011
Mao Z, Bozzella M, Seluanov A, Gorbunova V (2008) DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle 7:2902–2906. https://doi.org/10.4161/cc.7.18.6679
Maori E, Navarro IC, Boncristiani H et al (2019) A secreted RNA binding protein forms RNA-stabilizing granules in the Honeybee Royal Jelly. Mol Cell 74:598–608.e6. https://doi.org/10.1016/j.molcel.2019.03.010
Mazzu YZ, Armenia J, Chakraborty G et al (2019) A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2). Clin Cancer Res 25:4480–4492. https://doi.org/10.1158/1078-0432.CCR-18-4046
Mertz W (1974) The newer essential trace elements, chromium, tin, vanadium, nickel and silicon. Proc Nutr Soc 33:307–313. https://doi.org/10.1079/PNS19740054
Mesa RA, Loegering D, Powell HL et al (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106:318–327. https://doi.org/10.1182/blood-2004-09-3523
Miazzi C, Ferraro P, Pontarin G et al (2014) Allosteric regulation of the human and mouse deoxyribonucleotide triphosphohydrolase sterile α-motif/histidine-aspartate domain-containing protein 1 (SAMHD1). J Biol Chem 289:18339–18346. https://doi.org/10.1074/jbc.M114.571091
Milella M, Falcone I, Conciatori F et al (2015) PTEN: multiple functions in human malignant tumors. Front Oncol 5. https://doi.org/10.3389/fonc.2015.00024
Minnihan EC, Nocera DG, Stubbe J (2013) Reversible, long-range radical transfer in E. coli class Ia ribonucleotide reductase. Acc Chem Res 46:2524–2535. https://doi.org/10.1021/ar4000407
Misko TA, Wijerathna SR, Radivoyevitch T et al (2016) Inhibition of yeast ribonucleotide reductase by Sml1 depends on the allosteric state of the enzyme. FEBS Lett 590:1704–1712. https://doi.org/10.1002/1873-3468.12207
Misko TA, Liu Y-T, Harris ME et al (2019) Structure-guided design of anti-cancer ribonucleotide reductase inhibitors. J Enzyme Inhib Med Chem 34:438–450. https://doi.org/10.1080/14756366.2018.1545226
Mottram JC (1934) On the correlation between malignancy and the rate of growth of tar warts in mice. Am J Cancer 22:801–830. https://doi.org/10.1158/ajc.1934.801
Mun BJ, Mathews CK (1991) Cell cycle-dependent variations in deoxyribonucleotide metabolism among Chinese hamster cell lines bearing the Thy-mutator phenotype. Mol Cell Biol 11:20–26. https://doi.org/10.1128/MCB.11.1.20
Nagel R, Semenova EA, Berns A (2016) Drugging the addict: non-oncogene addiction as a target for cancer therapy. EMBO Rep 17(1516–1531):10.15252/embr.201643030
Nestoras K, Mohammed AH, Schreurs A-S et al (2010) Regulation of ribonucleotide reductase by Spd1 involves multiple mechanisms. Genes Dev 24:1145–1159. https://doi.org/10.1101/gad.561910
Niida H, Katsuno Y, Sengoku M et al (2010) Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase. Genes Dev 24:333–338. https://doi.org/10.1101/gad.1863810
Nunes C, Depestel L, Mus L, et al (2020) RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastoma. Cancer Biol
Offenbacher AR, Barry BA (2020) A proton wire mediates proton coupled electron transfer from hydroxyurea and other hydroxamic acids to tyrosyl radical in class Ia ribonucleotide reductase. J Phys Chem B 124:345–354. https://doi.org/10.1021/acs.jpcb.9b08587
Okat Z (2018) Clinical importance of glutathione-s-transferase enzyme polymorphisms in cancer. IPMRJ 3:10.15406/ipmrj.2018.03.00153
Okumura H, Natsugoe S, Yokomakura N et al (2006) Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 12:3740–3745. https://doi.org/10.1158/1078-0432.CCR-05-2416
Osako Y, Yoshino H, Sakaguchi T et al (2019) Potential tumor-suppressive role of microRNA-99a-3p in sunitinib-resistant renal cell carcinoma cells through the regulation of RRM2. Int J Oncol. https://doi.org/10.3892/ijo.2019.4736
Pajalunga D, Franzolin E, Stevanoni M et al (2017) A defective dNTP pool hinders DNA replication in cell cycle-reactivated terminally differentiated muscle cells. Cell Death Differ 24:774–784. https://doi.org/10.1038/cdd.2017.4
Parker WB, Shaddix SC, Chang CH et al (1991) Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51:2386–2394
Peris D, Janssen K, Barthel HJ et al (2020) DNA from resin-embedded organisms: past, present and future. PLoS One 15:e0239521. https://doi.org/10.1371/journal.pone.0239521
Pitsch S, Wendeborn S, Jaun B, Eschenmoser A (1993) Why pentose- and not hexose-nucleic acids? Part VII. Pyranosyl-RNA (‘P-RNA’). Preliminary communication. Helv Chim Acta 76:2161–2183. https://doi.org/10.1002/hlca.19930760602
Poole AM, Horinouchi N, Catchpole RJ et al (2014) The case for an early biological origin of DNA. J Mol Evol 79:204–212. https://doi.org/10.1007/s00239-014-9656-6
Prakasha Gowda AS, Polizzi JM, Eckert KA, Spratt TE (2010) Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase β and ligase III/XRCC1. Biochemistry 49:4833–4840. https://doi.org/10.1021/bi100200c
Puccetti MV, Adams CM, Kushinsky S, Eischen CM (2019) Smarcal1 and Zranb3 protect replication forks from Myc-induced DNA replication stress. Cancer Res 79:1612–1623. https://doi.org/10.1158/0008-5472.CAN-18-2705
Qi H, Lou M, Chen Y et al (2015) Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis. Tumor Biol 36:4833–4842. https://doi.org/10.1007/s13277-015-3137-4
Rampazzo C, Miazzi C, Franzolin E et al (2010) Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances. Mutat Res 703:2–10. https://doi.org/10.1016/j.mrgentox.2010.06.002
Rasmussen RD, Gajjar MK, Tuckova L et al (2016) BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity. Nat Commun 7:13398. https://doi.org/10.1038/ncomms13398
Reichard P, Baldesten A, Rutberg L (1961) Formation of deoxycytidine phosphates from cytidine phosphates in extracts from Escherichia coli. J Biol Chem 236:1150–1157. https://doi.org/10.1016/S0021-9258(18)64258-9
Reid G, Wallant NC, Patel R et al (2009) Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing 5:321–330
Richards RI (2001) Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet 17:339–345. https://doi.org/10.1016/S0168-9525(01)02303-4
Roberts EA, Deretic V (2008) Autophagic proteolysis of Long-lived proteins in nonliver cells. In: Deretic V (ed) Autophagosome and phagosome. Humana Press, Totowa, NJ, pp 111–117
Rudd SG, Tsesmetzis N, Sanjiv K et al (2020) Ribonucleotide reductase inhibitors suppress SAMHD 1 ara-CTP ase activity enhancing cytarabine efficacy. EMBO Mol Med 12:10.15252/emmm.201910419
Sabouri N, Viberg J, Goyal DK et al (2008) Evidence for lesion bypass by yeast replicative DNA polymerases during DNA damage. Nucleic Acids Res 36:5660–5667. https://doi.org/10.1093/nar/gkn555
Sagawa M, Ohguchi H, Harada T et al (2017) Ribonucleotide reductase catalytic subunit M1 (RRM1) as a novel therapeutic target in multiple myeloma. Clin Cancer Res 23:5225–5237. https://doi.org/10.1158/1078-0432.CCR-17-0263
Sampaio-Marques B, Guedes A, Vasilevskiy I et al (2019) α-Synuclein toxicity in yeast and human cells is caused by cell cycle re-entry and autophagy degradation of ribonucleotide reductase 1. Aging Cell 18. https://doi.org/10.1111/acel.12922
Sandvik GK, Tomter AB, Bergan J et al (2012) Studies of ribonucleotide reductase in crucian carp—an oxygen dependent enzyme in an anoxia tolerant vertebrate. PLoS One 7:e42784. https://doi.org/10.1371/journal.pone.0042784
Schmidt TT, Sharma S, Reyes GX et al (2019) A genetic screen pinpoints ribonucleotide reductase residues that sustain dNTP homeostasis and specifies a highly mutagenic type of dNTP imbalance. Nucleic Acids Res 47:237–252. https://doi.org/10.1093/nar/gky1154
Seedhouse C, Grundy M, Shang S et al (2009) Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine. Clin Cancer Res 15:7291–7298. https://doi.org/10.1158/1078-0432.CCR-09-1222
Sengupta R (2014) Thioredoxin and glutaredoxin-mediated redox regulation of ribonucleotide reductase. WJBC 5:68. https://doi.org/10.4331/wjbc.v5.i1.68
Sengupta R, Coppo L, Mishra P, Holmgren A (2019) Glutathione-glutaredoxin is an efficient electron donor system for mammalian p53R2–R1-dependent ribonucleotide reductase. J Biol Chem 294:12708–12716. https://doi.org/10.1074/jbc.RA119.008752
Shu Z, Li Z, Huang H et al (2020) Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition. Oncogene 39:5721–5733. https://doi.org/10.1038/s41388-020-01403-y
Singh S (2015) Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol 75:1–15. https://doi.org/10.1007/s00280-014-2566-x
Song Y, Marmion RA, Park JO et al (2017) Dynamic control of dNTP synthesis in early embryos. Dev Cell 42:301–308.e3. https://doi.org/10.1016/j.devcel.2017.06.013
Souglakos J, Boukovinas I, Taron M et al (2008) Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 98:1710–1715. https://doi.org/10.1038/sj.bjc.6604344
Specks J, Lecona E, Lopez-Contreras AJ, Fernandez-Capetillo O (2015) A single conserved residue mediates binding of the ribonucleotide reductase catalytic subunit RRM1 to RRM2 and is essential for mouse development. Mol Cell Biol 35:2910–2917. https://doi.org/10.1128/MCB.00475-15
Stodola JL, Burgers PM (2016) Resolving individual steps of Okazaki-fragment maturation at a millisecond timescale. Nat Struct Mol Biol 23:402–408. https://doi.org/10.1038/nsmb.3207
Stubbe J, Nocera DG, Yee CS, Chang MCY (2003) Radical initiation in the class I ribonucleotide reductase: long-range proton-coupled electron transfer? Chem Rev 103:2167–2202. https://doi.org/10.1021/cr020421u
Sumita K, Lo Y-H, Takeuchi K et al (2016) The lipid kinase PI5P4Kβ is an intracellular GTP sensor for metabolism and tumorigenesis. Mol Cell 61:187–198. https://doi.org/10.1016/j.molcel.2015.12.011
Sun H, Yang B, Zhang H et al (2019) RRM2 is a potential prognostic biomarker with functional significance in glioma. Int J Biol Sci 15:533–543. https://doi.org/10.7150/ijbs.30114
Szikriszt B, Póti Á, Pipek O et al (2016) A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol 17:99. https://doi.org/10.1186/s13059-016-0963-7
Tarangelo A, Dixon S (2018) The p53-p21 pathway inhibits ferroptosis during metabolic stress. Oncotarget 9(24572–24573):10.18632/oncotarget.25362
Tebbi A, Guittet O, Tuphile K et al (2015) Caspase-dependent proteolysis of human ribonucleotide reductase small subunits R2 and p53R2 during apoptosis. J Biol Chem 290:14077–14090. https://doi.org/10.1074/jbc.M115.649640
Teicher BA, Polley E, Kunkel M et al (2015) Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol Cancer Ther 14:2452–2462. https://doi.org/10.1158/1535-7163.MCT-15-0074
Thomas WC, Brooks FP, Burnim AA et al (2019) Convergent allostery in ribonucleotide reductase. Nat Commun 10:2653. https://doi.org/10.1038/s41467-019-10568-4
Tian H, Ge C, Li H et al (2014) Ribonucleotide reductase M2B inhibits cell migration and spreading by early growth response protein 1-mediated phosphatase and tensin homolog/Akt1 pathway in hepatocellular carcinoma. Hepatology 59:1459–1470. https://doi.org/10.1002/hep.26929
Tramentozzi E, Ferraro P, Hossain M et al (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102–1114. https://doi.org/10.1080/15384101.2018.1480216
Tu M, Li H, Lv N et al (2017) Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2. Mol Cancer 16:66. https://doi.org/10.1186/s12943-017-0619-6
Uramoto H, Sugio K, Oyama T et al (2006) P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res 26:983–988
Wang N, Zhan T, Ke T et al (2014) Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer 110:1034–1044. https://doi.org/10.1038/bjc.2013.817
Wang N, Li Y, Zhou J (2018) Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells. Oncol Lett. https://doi.org/10.3892/ol.2018.7806
Watson RA, Offenbacher AR, Barry BA (2021) Detection of catalytically linked conformational changes in wild-type class Ia ribonucleotide reductase using reaction-induced FTIR spectroscopy. J Phys Chem B 125:8362–8372. https://doi.org/10.1021/acs.jpcb.1c03038
Wisitpitthaya S, Zhao Y, Long MJC et al (2016) Cladribine and fludarabine nucleotides induce distinct hexamers defining a common mode of reversible RNR inhibition. ACS Chem Biol 11:2021–2032. https://doi.org/10.1021/acschembio.6b00303
Wu X, Huang M (2008) Dif1 controls subcellular localization of ribonucleotide reductase by mediating nuclear import of the R2 subunit. Mol Cell Biol 28:7156–7167. https://doi.org/10.1128/MCB.01388-08
Xie S, Luo H, Huang Y et al (2020) A missense mutation in a large subunit of ribonucleotide reductase confers temperature-gated tassel formation. Plant Physiol 184:1979–1997. https://doi.org/10.1104/pp.20.00219
Xu X, Page JL, Surtees JA et al (2008) Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res 68:2652–2660. https://doi.org/10.1158/0008-5472.CAN-07-5873
Xu Y, Singh A, Alter GM (2016) Hydroxyurea induces cytokinesis arrest in cells expressing a mutated sterol-14α-demethylase in the ergosterol biosynthesis pathway. Genetics 204:959–973. https://doi.org/10.1534/genetics.116.191536
Zhan Y, Jiang L, Jin X et al (2021) Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed Pharmacother 133:110996. https://doi.org/10.1016/j.biopha.2020.110996
Zhang K, Hu S, Wu J et al (2009) Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer 8:11. https://doi.org/10.1186/1476-4598-8-11
Zhang K, Wu J, Wu X et al (2011) p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol Cancer Ther 10:269–278. https://doi.org/10.1158/1535-7163.MCT-10-0728
Zhang H, Liu X, Warden CD et al (2014) Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers. BMC Cancer 14:664. https://doi.org/10.1186/1471-2407-14-664
Zhang J, Hou D, Annis J et al (2020) Inactivating mutations in exonuclease and polymerase domains in DNA polymerase delta alter sensitivities to inhibitors of dNTP synthesis. DNA Cell Biol 39:50–56. https://doi.org/10.1089/dna.2019.5125
Zhao X, Muller EGD, Rothstein R (1998) A suppressor of two essential checkpoint genes identifies a novel protein that negatively affects dNTP pools. Mol Cell 2:329–340. https://doi.org/10.1016/S1097-2765(00)80277-4
Zhao X, Wei C, Li J et al (2017) Cell cycle-dependent control of homologous recombination. Acta Biochim Biophys Sin 49:655–668. https://doi.org/10.1093/abbs/gmx055
Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808. https://doi.org/10.1056/NEJMoa065411
Zhong Z, Cao Y, Yang S, Zhang S (2016) Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-κB signaling pathway. Pharmazie 71:280–284
Zhou B-S, Tsai P, Ker R et al (1997) Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16:43–49. https://doi.org/10.1023/A:1006559901771
Zhou B, Shao J, Su L et al (2005) A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases. Mol Cancer Ther 4:1830–1836. https://doi.org/10.1158/1535-7163.MCT-05-0273
Zimanyi CM, Ando N, Brignole EJ et al (2012) Tangled up in knots: structures of inactivated forms of E. coli class Ia ribonucleotide reductase. Structure 20:1374–1383. https://doi.org/10.1016/j.str.2012.05.009
Zimanyi CM, Chen PY-T, Kang G, et al (2016) Molecular basis for allosteric specificity regulation in class Ia ribonucleotide reductase from Escherichia coli. eLife 5:e07141. https://doi.org/10.7554/eLife.07141
Zou Y, Zhou J, Xu B et al (2019) Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma. Onco Targets 12:3267–3275. https://doi.org/10.2147/OTT.S196347
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Long, M.J.C., Ly, P., Aye, Y. (2022). Still no Rest for the Reductases: Ribonucleotide Reductase (RNR) Structure and Function: An Update. In: Harris, J.R., Marles-Wright, J. (eds) Macromolecular Protein Complexes IV. Subcellular Biochemistry, vol 99. Springer, Cham. https://doi.org/10.1007/978-3-031-00793-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-031-00793-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-00792-7
Online ISBN: 978-3-031-00793-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)